BusinessAI imageCTNM Stock Drops 10% After JNJ Trial Failure
CTNM stock fell 10% after Johnson & Johnson announced that its mid-stage trial of JNJ-5120 (PIPE-307) for major depressive disorder did not meet its primary endpoint. This trial failure impacted investor confidence in CTNM.
Asianet Newsable·


